Modafinil

Modalert 200 mg Explained: Ingredients, Manufacturer & Product Details

Modalert 200 mg featured image showing modafinil tablet packaging, blister pack, ingredients, manufacturer information and pharmaceutical product details.

UK Clinical & Regulatory Disclaimer

 This article about Modalert 200 mg is provided for general educational and informational purposes only. It does not constitute medical advice, diagnosis or treatment guidance. Modafinil is a Prescription-Only Medicine (POM) in the UK, and the regulatory status of individual brands may differ. The information presented should not replace advice from a qualified healthcare professional. Always consult an appropriately qualified healthcare professional for questions concerning medicines or individual health circumstances.

Modalert 200 mg is a branded pharmaceutical tablet containing modafinil, an active ingredient found in prescription medicines for certain sleep-related conditions. The product belongs to the pharmaceutical portfolio of Sun Pharmaceutical Industries Ltd, commonly known as Sun Pharma.

For UK readers, understanding Modalert involves more than recognising its brand name or labelled strength. It is important to distinguish between the active ingredient, the manufacturer, the finished tablet formulation and the medicine’s regulatory status.

In the United Kingdom, modafinil is classified as a Prescription-Only Medicine (POM). However, this classification does not automatically mean that every internationally marketed modafinil brand has UK marketing authorisation.

This article examines Modalert 200 mg, including its active ingredient, manufacturer, pharmaceutical composition and available documentation. It also explains how branded medicines relate to generic terminology and why UK regulatory records must be considered separately from international product information.

What Is Modalert 200 mg?

Modalert 200 mg is a branded tablet containing 200 milligrams of modafinil. Sun Pharmaceutical Industries Ltd lists the product in its Indian pharmaceutical catalogue under the neurological and central nervous system (CNS) category.

Three details establish its basic pharmaceutical identity:

  • Brand name: Modalert
  • Active ingredient: Modafinil
  • Labelled strength: 200 mg per tablet

The brand name identifies a particular pharmaceutical product. By contrast, modafinil refers to the active substance responsible for its pharmacological action.

Therefore, Modalert is not a separate chemical compound. It is a branded formulation containing the established pharmaceutical ingredient modafinil.

The manufacturer’s official Sun Pharma product catalogue identifies Modalert tablets and confirms the listed active ingredient and strength.

Sun Pharmaceutical Industries Ltd.

However, a manufacturer’s international product listing does not establish UK marketing authorisation. That status depends on the relevant regulatory records for the individual medicine.

What Is the Active Ingredient in Modalert 200 mg?

Understanding Modafinil

Modafinil is the active pharmaceutical ingredient (API) in Modalert tablets.

An active pharmaceutical ingredient is the substance responsible for a medicine’s intended pharmacological action. It differs from the additional materials used to manufacture the finished tablet.

Modafinil belongs to a group of medicines described as wakefulness-promoting agents.

Within the UK regulatory framework, authorised modafinil medicines have a recognised indication involving excessive sleepiness associated with narcolepsy.

The MHRA guidance on restricted modafinil use explains the regulatory restriction of modafinil’s therapeutic indications.

GOV.UK

Furthermore, official UK pharmaceutical documentation describes individual authorised medicines containing modafinil, including their composition, licensed indications and manufacturing information.

Nevertheless, documentation for one authorised modafinil product should not automatically be applied to another formulation marketed under a different brand name.

Modalert as a Branded Modafinil Product

The expression Modalert modafinil describes the relationship between a pharmaceutical brand and its active ingredient.

Modafinil is the internationally recognised non-proprietary name of the substance. Modalert is a brand name associated with a finished medicine containing that ingredient.

This distinction is common in pharmaceutical naming. Different companies may market products containing the same active substance under separate brand names.

However, shared active ingredients do not necessarily mean that products have identical inactive ingredients, manufacturing specifications or regulatory documentation.

For additional context, the article explaining the difference between a modafinil brand and the active ingredient examines this distinction through Modvigil and modafinil terminology.

Consequently, understanding the difference between a brand name and an active ingredient helps readers interpret pharmaceutical information without assuming that different products are identical.

Who Manufactures Modalert 200 mg?

Modalert 200 mg is associated with Sun Pharmaceutical Industries Ltd, an international pharmaceutical company headquartered in India.

Sun Pharma includes Modalert tablets in its official Indian product portfolio. The manufacturer’s listing identifies modafinil as the active ingredient and confirms the product’s labelled strength.

The company operates across several pharmaceutical markets and therapeutic categories. Its portfolio includes medicines marketed under both branded and generic names.

The term Sun Pharma Modalert therefore refers to the product’s association with the pharmaceutical company.

However, pharmaceutical manufacturing records can distinguish between several organisations involved in a medicine’s production and distribution.

These may include:

  • Brand owner: The organisation associated with the commercial product name.
  • Manufacturing entity: The company responsible for producing a particular medicine or batch.
  • Marketing authorisation holder: The legal entity responsible for an authorised medicinal product within a specific regulatory market.
  • Importer or distributor: An organisation responsible for relevant supply-chain activities, where applicable.

These responsibilities do not necessarily belong to the same legal entity.

For example, a pharmaceutical company may own or market a brand while a separate manufacturing facility produces individual batches.

Therefore, identifying Sun Pharma as the company behind Modalert does not establish the exact manufacturing facility responsible for every product batch.

Similarly, the brand’s inclusion in Sun Pharma’s Indian product portfolio does not confirm its approval for the UK market.

The relevant packaging, manufacturer records and official regulatory documents determine these product-specific details.

Modalert 200 mg: Ingredients and Tablet Formulation

Understanding Modalert ingredients requires separating the confirmed active ingredient from the wider pharmaceutical formulation.

Active Ingredient and Labelled Strength

The confirmed active ingredient in Modalert 200 mg is modafinil.

According to Sun Pharma’s official product information, each tablet has a labelled modafinil strength of 200 mg.

This figure describes the amount of active pharmaceutical ingredient declared for the tablet. It does not represent the tablet’s total physical weight.

In addition to the active substance, finished pharmaceutical tablets commonly contain other ingredients that support their structure and manufacturing properties.

However, a basic product catalogue may not disclose the complete formulation.

The manufacturer information examined for this article confirms Modalert’s active ingredient, tablet form and labelled strength. It does not establish every component of the finished product.

Importantly, the labelled strength is a pharmaceutical identification detail. It should not be interpreted as an individual treatment recommendation.

Inactive Ingredients and Product Documentation

Inactive ingredients are commonly called excipients.

Manufacturers use excipients for functions such as forming the tablet, maintaining its physical structure, supporting stability or influencing how the formulation behaves.

Different modafinil tablet products may contain different excipients, even when their active ingredients and labelled strengths match.

For Modalert, a complete excipient list requires reliable documentation specific to the relevant formulation.

The manufacturer catalogue reviewed for this article does not provide a complete, independently verifiable list of inactive ingredients for Modalert 200 mg.

Therefore, ingredients documented for another modafinil medicine should not be presented as confirmed Modalert ingredients.

For example, an official UK Summary of Product Characteristics (SmPC) provides an excipient list for a specific modafinil tablet product authorised under a separate marketing authorisation.

That document concerns Milpharm’s modafinil tablets, not the Sun Pharma Modalert formulation. As a result, its excipient list cannot establish Modalert’s exact composition.

4320+1

Modalert 200 mg vs Generic Modafinil: Understanding the Terminology

The expressions Modalert, modafinil and generic modafinil are closely related, but they have different meanings.

Modalert is a pharmaceutical brand name. Modafinil is the non-proprietary name of its active ingredient.

The term generic medicine has a more specific meaning within pharmaceutical regulation.

Regulators assess generic medicines against relevant requirements concerning pharmaceutical quality and equivalence to an appropriate reference medicine.

However, an internationally marketed brand containing an established active ingredient does not automatically have formal generic authorisation in the UK.

Two tablets may share the same active ingredient and labelled strength while differing in their inactive ingredients, manufacturing specifications or approved documentation.

Similarly, matching pharmaceutical ingredient names do not independently establish equivalent regulatory assessments.

A related article discusses the differences between Modvigil 200 mg and Modalert 200 mg, focusing on the distinction between two branded products containing modafinil.

For broader background, the forthcoming comprehensive Modalert guide will bring together the brand’s wider pharmaceutical and regulatory context.

Nevertheless, the central distinction remains straightforward: a brand name identifies a product, an active ingredient identifies a pharmaceutical substance, and generic authorisation depends on applicable regulatory requirements.

Modalert 200 mg vs generic modafinil infographic explaining brand names, active ingredients, formulation differences and UK regulatory status.
Modalert 200 mg vs generic modafinil mobile infographic comparing brand names, active ingredients, formulation differences and UK regulatory status.

What Should UK Readers Know About Modalert Product Information?

For UK readers, pharmaceutical product identity and marketing authorisation are separate matters.

Modafinil is classified as a Prescription-Only Medicine in the United Kingdom. Its supply and promotion are therefore subject to the relevant medicines legislation.

The Medicines and Healthcare products Regulatory Agency (MHRA) oversees the regulation of medicines in the UK.

A marketing authorisation applies to a defined medicinal product. It does not automatically extend to every internationally marketed brand containing the same active substance.

Consequently, identifying modafinil as an ingredient in UK-authorised medicines does not establish UK marketing authorisation for Modalert.

The official sources examined for this article do not establish a UK marketing authorisation specifically under the Modalert brand name.

This finding should not be interpreted as a complete determination of every possible regulatory or supply arrangement. Rather, it distinguishes the verified international manufacturer listing from UK authorisation evidence.

The MHRA provides guidance on finding official medicine product information, including Summaries of Product Characteristics, patient information leaflets and public assessment reports.

GOV.UK

These records help distinguish product-specific regulatory information from general descriptions of an active ingredient.

For example:

  • Manufacturer catalogues identify medicines within a company’s portfolio.
  • MHRA product records provide information about relevant UK marketing authorisations.
  • SmPCs describe the approved characteristics of specific authorised medicines.
  • Patient information leaflets present approved information for the corresponding product.

Additionally, marketing authorisation arrangements may differ across European countries. A medicine’s status in one jurisdiction should not be assumed to apply throughout the UK and European Union.

The broader Modafinil UK category provides additional educational context concerning modafinil-related terminology and product information. 

The distinction is especially important when researching brands that appear in international pharmaceutical catalogues but lack readily established UK-specific authorisation records.

Modalert 200 mg: Key Product Facts at a Glance

Product detail

Verified information

Brand name

Modalert

Active ingredient

Modafinil

Labelled strength

200 mg per tablet

Pharmaceutical form

Tablet

Manufacturer / brand association

Sun Pharmaceutical Industries Ltd

Pharmaceutical category

Wakefulness-promoting medicine

Manufacturer reference

Sun Pharma’s Indian pharmaceutical product catalogue

UK ingredient classification

Modafinil is a Prescription-Only Medicine (POM)

UK marketing authorisation

Not established for the Modalert brand from the sources examined

Complete inactive ingredient list

Not independently verified for the specific Modalert formulation

Regulatory distinction

UK authorisation must be established for the individual medicinal product

Modalert 200 mg infographic showing active ingredient, manufacturer, tablet strength, pharmaceutical category, and UK regulatory information.
Modalert 200 mg mobile infographic showing modafinil ingredient, manufacturer details, tablet strength, and UK prescription-only classification. Copy Alt Text

These details summarise the product’s verified identity while distinguishing international manufacturer information from UK regulatory authorisation.

Frequently Asked Questions

What is the main ingredient in Modalert 200 mg?

The active ingredient is modafinil, with a labelled strength of 200 mg per tablet. Sun Pharmaceutical Industries confirms this information in its official Indian product catalogue. Modafinil is the active pharmaceutical substance, while Modalert is the brand name. The finished tablet may contain additional inactive ingredients, but their complete composition requires reliable documentation specific to the formulation.

Modalert is associated with Sun Pharmaceutical Industries Ltd, commonly called Sun Pharma. The company includes the brand in its Indian pharmaceutical portfolio and identifies modafinil as its active ingredient. However, the brand owner, manufacturing entity and marketing authorisation holder can be separate organisations. Identifying the manufacturing responsibility for a particular batch requires the relevant product documentation.

Modalert contains modafinil, an active ingredient also present in other branded and generic medicines. Nevertheless, sharing an ingredient and labelled strength does not automatically establish identical formulations or equivalent regulatory status. Formal generic authorisation depends on pharmaceutical quality requirements and applicable regulatory assessments. Therefore, Modalert’s identity as a branded modafinil product should be distinguished from its formal authorisation status.

Modafinil is a prescription-only medicine in the UK, but individual brands require their own applicable regulatory authorisation. The official documentation examined for this article does not establish a UK marketing authorisation specifically under the Modalert brand name. Its presence in Sun Pharma’s Indian product catalogue confirms its international product identity, not approval by the MHRA for the UK market.

Final Summary

Modalert is a branded pharmaceutical tablet associated with Sun Pharmaceutical Industries Ltd. Its defining characteristics are the Modalert brand name, modafinil active ingredient and labelled strength.

The manufacturer’s official product catalogue confirms these basic details. However, a complete pharmaceutical description also depends on formulation-specific documentation, including reliable information about inactive ingredients and manufacturing responsibility.

For UK readers, the distinction between an internationally marketed pharmaceutical brand and a UK-authorised medicinal product is particularly important.

Modafinil’s prescription-only classification does not independently establish the regulatory status of every brand containing the ingredient.

Understanding these differences provides a clearer foundation for interpreting Modalert product information without confusing brand identity, pharmaceutical composition or marketing authorisation.

author-avatar

About Waklert Store Research Desk

Waklert Store Research Desk is the internal editorial team behind Waklert Store's educational content on Modafinil and Armodafinil. All articles are prepared using publicly available medical references, UK regulatory guidance, and internal editorial review standards.View all posts by Waklert Store Research Desk

Leave a Reply

Your email address will not be published. Required fields are marked *